Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2025-05-05 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL Biosciences annonce les résultats d’une nouvelle étude menée avec le CEA permettant de mieux décrire l’effet de NFL-101, son traitement first in class contre l’addiction au tabac, mettant notammen
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces the results of a new study conducted with the CEA regarding NFL-101, a treatment for tobacco addiction. It details scientific findings, quotes the CEO, and provides context on the drug's efficacy and mechanism of action. This format—a formal announcement of new scientific or business developments, often released to the public and media—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it is announcing new data/results, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's an ad-hoc announcement. Given the content is a scientific update rather than a summary of quarterly financial performance, and it is a press release format, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although ER is sometimes used for significant operational updates. However, since it is a press release announcing scientific progress, and not explicitly an 'Earnings Release' summarizing financial results for a period, RNS is the safer general classification for non-standard announcements. The document length (7660 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA). I will classify it as RNS as it is a general regulatory/corporate announcement.
2025-05-05 French
Marex Group initiates coverage of NFL Biosciences with a Buy rating
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press release" and announces that Marex Group has initiated analyst coverage of NFL Biosciences with a Buy rating and a price target. This type of announcement, which communicates external market analysis or rating changes, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER, or DIV). It is a general corporate communication regarding market perception and analyst activity. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), and it is not a presentation (IP) or a transcript (CT), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that don't fit elsewhere.
2025-04-24 English
Marex Group initie à l’achat la couverture de NFL Biosciences
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Marex Group has initiated analyst coverage on NFL Biosciences, recommending a 'buy' with a specific price target (€3.60). This announcement concerns the initiation of research coverage and investment analysis, which is a form of communication directed at investors regarding the company's valuation and prospects. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV), fits best under the general category of Investor Relations communication. Since there is no specific code for 'Analyst Coverage Initiation,' and it is a formal announcement intended for the investment community, it is classified as Investor Relations (IR). The document is short and is an announcement about an external action (analyst coverage), not the primary financial report itself.
2025-04-24 French
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2024
Report Publication Announcement Classification · 98% confidence The document is a press release titled "NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2024" (NFL Biosciences announces the availability of its 2024 annual financial report). It explicitly states that the annual financial report (which includes the management report, corporate governance report, annual accounts, and auditor reports) has been made available to the public and filed with the AMF. The document itself is short (2466 characters) and serves only to announce the publication of the full report, not to contain the full report's content. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points to a Report Publication Announcement (RPA).
2025-04-15 French
NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Earnings Release Classification · 100% confidence The document is explicitly titled "Press release" and announces the company's "2024 annual results and provides an update on its clinical program." It details financial results for the year ended December 31, 2024, approved on April 10, 2025. This structure—announcing annual financial results and providing operational updates in a press release format—is characteristic of an Earnings Release (ER). While it contains comprehensive operational updates that might resemble parts of an Annual Report (10-K) or Management Discussion & Analysis (MDA), the format and primary function here is the initial public announcement of the yearly financial performance highlights, which aligns best with the Earnings Release (ER) definition. It is not a full 10-K, nor is it a transcript (CT) or a dedicated presentation (IP). FY 2024
2025-04-11 English
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son programme clinique
Earnings Release Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces the company's financial results for the fiscal year ended December 31, 2024, alongside significant clinical updates for its main drug candidate, NFL-101. The text explicitly states: "NFL BIOSCIENCES... annonce aujourd'hui ses résultats financiers pour l'exercice clos le 31 décembre 2024..." (announces today its financial results for the fiscal year ended December 31, 2024). This structure—a press release summarizing annual financial performance and operational highlights—is characteristic of an Earnings Release (ER). While it contains annual financial data, it is presented as a summary announcement rather than the comprehensive, audited 10-K filing. It is too detailed for a simple Report Publication Announcement (RPA) and covers more than just the initial financial highlights, but its primary function here is the release of the annual financial summary. Given the focus on the 'résultats annuels 2024' (annual results 2024) presented via a press release format, the most appropriate classification is Earnings Release (ER). FY 2024
2025-04-11 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.